خانه › میلوم متعدد › نیویورک › New York City
آزمایش‌های بالینی میلوم متعدد در New York City، NY
60 مطالعه برای میلوم متعدد در مراکز New York City (در شعاع حدود ۳۰ مایل) در جستجوی شرکت‌کننده هستند. یک مطالعه را باز کنید تا شرایط شرکت و نحوه تماس با تیم پژوهشی را ببینید.
متن رسمی مطالعه (انگلیسی)
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
در حال جذب شرکت‌کنندهمرحله 2
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
در حال جذب شرکت‌کننده
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Limited-duration Teclistamab
در حال جذب شرکت‌کنندهمرحله 2
- Columbia University, New York
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
در حال جذب شرکت‌کنندهمرحله 2
- Memorial Sloan Kettering Cancer Center (All protocol activities), New York
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
در حال جذب شرکت‌کنندهمرحله 3
- Research Site, New York
- Research Site, New York
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
در حال جذب شرکت‌کنندهمرحله 1
- Icahn School of Medicine at Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 1/2
- Memorial Sloan Kettering Cancer Center Mskcc, New York
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
در حال جذب شرکت‌کنندهمرحله 4
- Mount Sinai Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 3
- Mount Sinai Chelsea, New York
- Laura and Isaac Perlmutter Cancer Center NYU ACC, New York
- Icahn School of Medicine at Mount Sinai, New York
- و 1 مورد دیگر
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 3
- NYU Langone Health Manhattan, New York
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
در حال جذب شرکت‌کنندهمرحله 3
- Memorial Sloan Kettering Cancer Center, New York
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
در حال جذب شرکت‌کنندهمرحله 1
- Research Site, New York
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
در حال جذب شرکت‌کنندهمرحله 2
- Icahn School of Medicine at Mt. Sinai, New York
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
در حال جذب شرکت‌کنندهمرحله 3
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center-Main Campus, New York
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 1/2
- Memorial Sloan Kettering, New York
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 2
- Mount Sinai Medical Center, New York
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 3
- Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College, New York
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 1/2
- Tisch Cancer Institute at Mount Sinai, New York
- Memorial Sloan-Kettering Cancer Center, New York
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
در حال جذب شرکت‌کنندهمرحله 2
- Manhattan Eye, Ear, and Throat Hospital, New York
- Staten Island University Hospital, New York
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
در حال جذب شرکت‌کنندهمرحله 2/3
- Icahn School of Medicine at Mount Sinai /ID# 277844, New York
- Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 277946, New York
- Weill Cornell Medicine Myeloma Center /ID# 278216, New York
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
در حال جذب شرکت‌کنندهمرحله 3
- David H. Koch Center for Cancer Care, New York
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 1/2
- Mount Sinai, The Tisch Cancer Instutute, New York
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
در حال جذب شرکت‌کنندهمرحله 3
- Weill Cornell Medical College, New York
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 2
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
در حال جذب شرکت‌کنندهمرحله 2
- Icahn School of Medicine at Mount Sinai, New York
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
در حال جذب شرکت‌کنندهمرحله 1/2
- Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 271214, New York
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai，The Tisch Cancer Institute, New York
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
در حال جذب شرکت‌کنندهمرحله 3
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 1/2
- Research Site, New York
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 1
- Memorial Sloan-Kettering Cancer Center, New York
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
در حال جذب شرکت‌کنندهمرحله 1/2
- Research Site, New York
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
در حال جذب شرکت‌کنندهمرحله 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
در حال جذب شرکت‌کنندهمرحله 1
- Memorial Sloan Kettering Cancer Center, New York
Delayed Toxicities Post-CAR-T
در حال جذب شرکت‌کنندهمطالعه مشاهده‌ای
- Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
در حال جذب شرکت‌کنندهمطالعه مشاهده‌ای
- Weill Cornell Medical Center (Data Analysis Only), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 2
- The Tisch Cancer Institute/Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
در حال جذب شرکت‌کنندهمرحله 1/2
- Mount Sinai - The Tisch Cancer Institute /ID# 272470, New York
- Weill Cornell Medical College /ID# 272517, New York
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 1
- Laura and Isaac Perlmutter Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 1
- Mt Sinai /ID# 251166, New York
- Memorial Sloan Kettering Cancer Center-Koch Center /ID# 251167, New York
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
در حال جذب شرکت‌کنندهمرحله 1
- Weill Cornell Medicine/New York Presbyterian Hospital, New York
- New York Presbyterian Hospital Columbia University Medical Center, New York
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
در حال جذب شرکت‌کنندهمرحله 2
- Weill Cornell Medical Center (Data Collection Only), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
The Ambient Light Multiple Myeloma Study
در حال جذب شرکت‌کننده
- Icahn Schoool of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
در حال جذب شرکت‌کنندهمرحله 3
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
در حال جذب شرکت‌کننده
- Icahn School of Medicine at Mount Sinai, New York
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
در حال جذب شرکت‌کنندهمرحله 3
- Mount Sinai Medical Center - 2, New York
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
در حال جذب شرکت‌کنندهمرحله 1/2
- Perlmutter Cancer Center, New York
- Columbia University _ New York Presbyterian, New York
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 1
- Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 270282, New York
A Dietary Study for People With Multiple Myeloma
در حال جذب شرکت‌کننده
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
در حال جذب شرکت‌کنندهمرحله 3
- GSK Investigational Site, New York
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 1/2
- Icahn School of Medicine at Mount Sinai, New York
Study of CAR-T Therapy in Older Patients
در حال جذب شرکت‌کنندهمطالعه مشاهده‌ای
- Memorial Sloan Kettering Cancer Center, New York
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 1
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
در حال جذب شرکت‌کنندهمرحله 2
- Memorial Sloan Kettering Cancer Center, New York
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
در حال جذب شرکت‌کنندهمرحله اول اولیه
- Memorial Sloan Kettering Cancer Center, New York
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
در حال جذب شرکت‌کنندهمطالعه مشاهده‌ایپذیرش داوطلبان سالم
- Memorial Sloan Kettering Cancer Center, New York
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 1
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
در حال جذب شرکت‌کنندهمرحله 1/2
- Memorial Sloan Kettering Cancer Center, New York
آزمایش‌های میلوم متعدد در سایر شهرها
- Atlanta, GA42 مطالعه
- Boston, MA42 مطالعه
- Houston, TX38 مطالعه
- Durham, NC37 مطالعه
- Nashville, TN32 مطالعه
- Denver, CO27 مطالعه
- Rochester, MN24 مطالعه
- St. Louis, MO24 مطالعه
- Columbus, OH24 مطالعه
- Baldwin Park, CA23 مطالعه
- Chicago, IL22 مطالعه
- Edison, NJ22 مطالعه
سایر مطالعات در New York City
- سرطان پستان136 مطالعه
- سرطان ریه غیرسلول کوچک121 مطالعه
- سرطان (همه انواع)109 مطالعه
- سرطان پروستات103 مطالعه
- سرطان متاستاتیک93 مطالعه
- سرطان کولورکتال78 مطالعه
- سرطان تخمدان69 مطالعه
- سرطان ریه60 مطالعه
- سرطان لوزالمعده60 مطالعه
- سرطان آندومتر52 مطالعه
- لوکمیه حاد میلویید51 مطالعه
- نارسایی قلبی51 مطالعه
از ClinicalTrials.gov، داده‌ها در تاریخ 6 اکتبر 2026 دریافت شده است. هر مطالعه شرایط اختصاصی خود را دارد؛ تیم پژوهشی تصمیم می‌گیرد چه کسانی می‌توانند شرکت کنند.